INVESTORS & MEDIA
Corporate Governance
Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
---|---|---|---|---|---|---|---|
Jan 05, 2005 |
SVP, PreclinDevel & Biomol Sci
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | 94,851 | -- | -- |
Aug 04, 2022 |
EVP Research and Development
|
EVP Research and Development | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 95,000 | $270.43 | 147,795 |
Aug 04, 2022 |
EVP Research and Development
|
EVP Research and Development | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 95,000 | -- | -- |
Dec 13, 2013 |
SVP Research and Development S
|
SVP Research and Development S | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 95,000 | -- | 95,000 |
Jun 18, 2012 |
SVP Res & Dev Sciences
|
SVP Res & Dev Sciences | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 95,079 | $20.32 | 154,200 |
Jun 18, 2012 |
SVP Res & Dev Sciences
|
SVP Res & Dev Sciences | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 95,079 | -- | -- |
Dec 18, 2006 |
SVP, Therap & Clin Prog Dev
|
SVP, Therap & Clin Prog Dev | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 95,079 | -- | 95,079 |
Dec 17, 2007 |
SVP, Research & Devel Sciences
|
SVP, Research & Devel Sciences | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 95,438 | -- | 95,438 |
Jan 05, 2005 |
SVP, PreclinDevel & Biomol Sci
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | 100,000 | -- | -- |
Dec 14, 2012 |
SVP Res and Devel Sciences
|
SVP Res and Devel Sciences | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 112,500 | -- | 112,500 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.